Please assess the completion status of the following clinical trial:

Trial Title: A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering at least 10% of body surface area~* A Psoriasis Area and Severity Index (PASI) score of 12 or greater~* Are considered to be candidates for systemic or light therapy~* Have no evidence of active or latent tuberculosis~Exclusion Criteria:~* Non-plaque or drug-induced forms of psoriasis~* Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)~* Any uncontrolled significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment 10 mg BID (Type: EXPERIMENTAL): None
- Active Treatment 5 mg BID (Type: EXPERIMENTAL): None
- Placebo Treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).